Liminatus Pharma (LIMN) Cash from Financing Activities (2024 - 2026)
Liminatus Pharma (LIMN) posted Cash from Financing Activities of $3.6 million for Q1 2026, down 65.26% sequentially from $10.3 million in Q2 2025, and up 402.85% YoY from $713000.0 in Q1 2025.
Liminatus Pharma (LIMN) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Cash from Financing Activities for 3 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 402.85% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (changed N/A YoY) and the FY2025 annual result came in at $11.0 million, up 181.23% from the prior year.
- Cash from Financing Activities eased to $3.6 million in Q1 2026 per LIMN's latest filing, from $10.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.3 million in Q2 2025 and troughed at $700000.0 in Q4 2024.
- A 3-year average of $3.3 million and a median of $1.0 million in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 402.85% in 2026, down 402.85% in 2026.
- Over 3 years, Cash from Financing Activities stood at $700000.0 in 2024, then jumped by 1374.25% to $10.3 million in 2025, then plunged by 65.26% to $3.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.6 million, $10.3 million, and $713000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Jun 30, 2025 | 10.32 Mn |
| Jun 30, 2025 | 10.32 Mn |
| Mar 31, 2025 | 713,000.00 |
| Mar 31, 2025 | 713,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.02 Mn |